Breast Cancer Drug Aromasin May Be Option for Some Premenopausal Women

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

It produced lower 5-year recurrence rates compared to tamoxifen, but didn't boost overall survival, study finds

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.